BioCentury
ARTICLE | Company News

GeneriCo wins IPR for Apriso

June 16, 2017 8:51 PM UTC

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX). The IPR petition was filed by generics company GeneriCo LLC (St. Louis, Mo.).

Salix Pharmaceuticals Ltd., which Valeant acquired in 2015, had U.S. rights to Apriso from Dr. Falk Pharma GmbH (Freiburg, Germany) (see BioCentury, March 23, 2009 & April 6, 2015)...